ESMO26: Sac-TMT sets survival benchmark in recurrent endometrial cancer

Data for MSD and Kelun-Biotech’s sac-TMT in endometrial cancer was presented at ESMO 2026.

Source: Pharmaceutical Technology, 2026-10-27. Third-party report, linked to its original publisher; IC360 has not independently verified it.